GlassScriptPhysician profile
Jennifer Peek
NPI 1568660181
$2,671.32
in general payments reported to CMS, 2019-2025
20 companies · $609 in 2025
The $609 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $356 · 2021: $587 · 2022: $513 · 2023: $153 · 2024: $281 · 2025: $609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $571.76 | 2019-2022 | |
| Alcon Vision LLC | $400.22 | 2022-2025 | Clareon Panoptix Pro, Clareon, Dailies |
| Novartis Pharmaceuticals Corporation | $224.60 | 2020-2023 | |
| Abbvie INC. | $218.41 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $217.80 | 2022-2024 | Cequa |
| Tarsus Pharmaceuticals, INC. | $186.36 | 2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $145.85 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $131.40 | 2019-2021 | |
| Oyster Point Pharma, INC. | $125.31 | 2022-2025 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $114.97 | 2024 | |
| Dompe US, INC. | $64.18 | 2025 | Oxervate |
| Horizon Therapeutics Plc | $60.22 | 2022 | |
| Carl Zeiss Meditec, INC. | $45.78 | 2020 | |
| Eyevance Pharmaceuticals LLC | $34.33 | 2020 | |
| Bausch & Lomb Americas INC. | $29.98 | 2022-2025 | Scoutpro Osmolarity System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $27.03 | 2021 | |
| Glaukos Corporation | $22.70 | 2025 | Idosetr |
| Shire North American Group INC | $20.63 | 2019 | |
| Biotissue Holdings INC. | $16.87 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $12.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Peek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.